To hear about similar clinical trials, please enter your email below
Trial Title:
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers
NCT ID:
NCT06133790
Condition:
Head and Neck Cancer
Conditions: Official terms:
Head and Neck Neoplasms
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Genetic
Intervention name:
PCR - Immunohistochemistry - Immunolabelling
Description:
Genetic analysis will be conducted on biopsy to define molecular profile of head and neck
tumors
Arm group label:
HPV + Group
Arm group label:
HPV - Group
Summary:
Squamous cell cancers of the head and neck are classically correlated to excessive
consumption of alcohol and tobacco and have a rather poor prognosis. However, the
incidence of Head and Neck cancers in patients without alcohol-smoking risk factor has
continued to increase in recent years, in relation to more and more frequent HPV
contamination.
Some studies show a difference in the expression of certain genes within the two groups
of tumors (HPV+ and HPV-) including some that confer sensitivity to certain
chemotherapies and others to radiotherapy. However, patients with HPV+ Head and Neck
cancers are treated according to the same referential as HPV- Head and Neck cancers.
There is therefore a real need for studies identifying predictive markers in order to be
able to offer patients a more effective suitable and less invasive treatment.
Detailed description:
Head and neck cancers are the sixth most common cancer common worldwide causing more than
380,000 deaths each year. More than 90% of these cancers are carcinomas epidermoids
arising from the mucosal surfaces of the cavity oral cavity, oropharynx and larynx.
Squamous cell cancers of the head and neck are classically correlated with risk factors
linked to excessive consumption of alcohol and tobacco and have a rather poor prognosis
(mainly HPV (Human Papilloma Virus) negative patients).
However, the incidence of Head and Neck cancers in patients without alcohol-smoking risk
factor has continued to increase in recent years, in relation to more and more frequent
HPV contamination. Evolution of oral sexual practices seems to be one of the explanations
for the progression of these cases of oropharyngeal squamous cell carcinoma and oral
cavity HPV positive.
Some studies show a difference in the expression of certain genes within the two groups
of tumors (HPV+ and HPV-) including some that confer sensitivity to certain
chemotherapies (CCND1, TYMS) and others to radiotherapy (RBBP4). However, patients with
HPV+ Head and Neck cancers are treated according to the same referential as HPV- Head and
Neck cancers. There is therefore a real need for studies identifying predictive markers
in order to be able to offer patients a more effective suitable and less invasive
treatment. This is the context of this research project.
Criteria for eligibility:
Study pop:
Patient with Head and Neck cancer and HPV diagnosis
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patient with oropharyngeal squamous cell carcinoma or the oral cavity histologically
proven.
- Primary tumor for which a biopsy or excision is required available and sufficient to
carry out molecular analysis
Exclusion Criteria:
- Patient with Head and Neck cancer other than oropharyngeal or oral cavity squamous
cells carcinomas
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hôpital Privé Clairval
Address:
City:
Marseille
Zip:
13009
Country:
France
Status:
Recruiting
Contact:
Last name:
Jérôme PARIS, MD
Phone:
+ 33 4 91 17 17 70
Email:
j.paris@me.com
Start date:
January 1, 2024
Completion date:
June 30, 2024
Lead sponsor:
Agency:
GCS Ramsay Santé pour l'Enseignement et la Recherche
Agency class:
Other
Source:
GCS Ramsay Santé pour l'Enseignement et la Recherche
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06133790
